Study ID | Sample size (E/C) | Adverse events cases | Experimental group (n) | Control group (n) |
---|---|---|---|---|
Duan CR 2017 [13] | 36/36 | E:0/36; C:0/36 | Reported no occurrence | Reported no occurrence |
Han DX 2014 [14] | 38/35 | E:2/38; C:7/35 | Hypertension; secondary infection (Total 2) | Hypertension; secondary infection; mental symptoms (Total 7) |
Lu W 2015 [15] | 20/20 | E:6/20; C:7/20 | Adverse reaction of glucocorticoid (2) gastrointestinal discomfort (3) respiratory tract infection (1) | Adverse reaction of glucocorticoid (3) gastrointestinal discomfort (3) respiratory tract infection (1) |
Peng YH 2014 [16] | 28/26 | E:NR; C:NR | NR | NR |
Shi Z 2019 [17] | 15/15 | E:1/15; C:6/15 | Diarrhea (1) | Itching(1), diarrhea(2), rash(1), nausea(1), dizziness (1) |
Yuan TT 2020 [18] | 47/47 | E:NR; C:NR | NR | NR |
Zhou DJ a 2013 [19] | 10/10 | E:NR; C:NR | NR | NR |
Zhou DJ b 2013 [19] | 5/5 | E:NR; C:NR | NR | NR |